Swiss National Bank grew its stake in shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) by 12.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 109,642 shares of the biopharmaceutical company’s stock after purchasing an additional 12,300 shares during the quarter. Swiss National Bank owned about 0.16% of Alder Biopharmaceuticals worth $1,255,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of ALDR. SG Americas Securities LLC acquired a new position in shares of Alder Biopharmaceuticals during the 4th quarter worth approximately $132,000. Jane Street Group LLC acquired a new position in shares of Alder Biopharmaceuticals during the 3rd quarter worth approximately $184,000. Teacher Retirement System of Texas acquired a new position in shares of Alder Biopharmaceuticals during the 4th quarter worth approximately $231,000. Voya Investment Management LLC boosted its stake in shares of Alder Biopharmaceuticals by 8.4% during the 2nd quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 1,734 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Alder Biopharmaceuticals by 611.7% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 23,373 shares of the biopharmaceutical company’s stock worth $286,000 after acquiring an additional 20,089 shares during the period. 99.14% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently commented on the company. Mizuho reiterated a “buy” rating and set a $29.00 target price on shares of Alder Biopharmaceuticals in a research note on Wednesday, January 31st. Canaccord Genuity set a $22.00 target price on Alder Biopharmaceuticals and gave the stock a “buy” rating in a research note on Friday, January 12th. BMO Capital Markets reiterated a “buy” rating and set a $22.00 target price on shares of Alder Biopharmaceuticals in a research note on Wednesday, January 3rd. ValuEngine upgraded Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 4th. Finally, BidaskClub upgraded Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $28.14.
Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.03) by $0.23. The firm had revenue of $0.94 million during the quarter. During the same period in the previous year, the business earned ($0.97) EPS. research analysts forecast that Alder Biopharmaceuticals Inc will post -4.24 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Alder Biopharmaceuticals Inc (ALDR) Holdings Lifted by Swiss National Bank” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/03/14/alder-biopharmaceuticals-inc-aldr-holdings-lifted-by-swiss-national-bank.html.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.